Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study

References

• Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod. 2004;10:409–419.
   Web of Science ®Google Scholar
• Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol. 2006;65:275–281.
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Haider KS, et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;12:251–261.
   PubMed Web of Science ®Google Scholar
• Behre HM, Wang C, Handelsman DJ, et al. 2004. Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM, editors. Testosterone, action, deficiency, substitution. Cambridge (UK): Cambridge University Press. p. 405–444.
   Google Scholar
• Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 2004;89:5429–5434.
   PubMed Web of Science ®Google Scholar
• Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother. 2005;6:1751–1759.
   PubMed Web of Science ®Google Scholar
• Saad F, Kamischke A, Yassin A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Andrology. 2007;9:291–297.
   PubMed Web of Science ®Google Scholar
• Gooren LJ. Advances in testosterone replacement therapy. Front Horm Res. 2009;37:32–51.
   PubMed Web of Science ®Google Scholar
• Moisey R, Swinburne J, Orme S. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM–Nebido). Clin Endocrinol. 2008;69:642–647.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91:4335–4343.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2009;181:972–979.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®). World J Urol. 2006;24:639–644.
   PubMed Web of Science ®Google Scholar
• Jo DG, Lee HS, Joo YM, et al. Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Med J. 2013;54:1331–1335.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract. 2014;68:203–215.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Doros G, et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I–III: observational data from two registry studies. Int J Obes. 2016;40:162–170.
   PubMed Web of Science ®Google Scholar
• Gooren L. Diagnosing hypogonadism and treating decisions in different parts of the world: shifts in patterns between 2006 and 2015. Aging Male. 2016;19:46–53.
   PubMed Web of Science ®Google Scholar
• Yassin A, Salman M, Talib RA, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20:125–133.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1438 men. J Sex Med. 2013;10:579–588.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Nettleship J, Almehmadi Y, et al. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia. 2016;48:793–799.
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Doros G, et al. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515.
   PubMed Web of Science ®Google Scholar
• Conaglen HM, Paul RG, Yarndley T, et al. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. J Sex Med. 2014;11:574–582.
   PubMed Web of Science ®Google Scholar
• Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol. 1994;40:341–349.
   PubMed Web of Science ®Google Scholar
• Coward RM, Simhan J, Carson Iii CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009;103:1179–1183.
   PubMed Web of Science ®Google Scholar
• Tan WS, Low WY, Ng CJ, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111:1130–1140.
   PubMed Web of Science ®Google Scholar
• Morrison BF, Reid M, Madden W, et al. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology. 2013;1:576–582.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest. 2010;33:776–783.
   PubMed Web of Science ®Google Scholar
• Moon DG, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010;7:2253–2260.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10:1612–1627.
   PubMed Web of Science ®Google Scholar
• Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99:3821–3828.
   PubMed Web of Science ®Google Scholar
• Haider A, Meergans U, Traish A, et al. Progressive improvement of T-scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol. 2014;2014:496948.
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Khupulsup K, Leelaphiwat S, et al. Effects of 8-year treatment of long-acting testosterone undecanoate on metabolic parameters, urinary symptoms, bone mineral density, and sexual function in men with late-onset hypogonadism. J Sex Med. 2016;13:1199–1211.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2015;15:1903–1926.
   Web of Science ®Google Scholar